US005661180A

United States Patent [19]

DeMichele et al.

[11] Patent Number: 5,661,180

[45] Date of Patent: Aug. 26, 1997

[54] **STRUCTURED LIPID CONTAINING GAMA-LINOLENIC OR DIHOGAMMA-LINOLENIC FATTY ACID RESIDUE, A MEDIUM CHAIN (C_6-C_{12}) FATTY ACID RESIDUE, AND A N-3 FATTY ACID RESIDUE**

[75] Inventors: **Stephen Joseph DeMichele**, Dublin, Ohio; **Michael Donald Karlstad**, Knoxville, Tenn.; **Bruce Ryan Bistrian**, Ipswich; **Edward Anthony Mascioli**, Needham, both of Mass.

[73] Assignees: **Abbott Laboratories**, Abbott Park, Ill.; **New England Deaconess Hospital**, Boston, Mass.; **University of Tennessee Research Corporation**, Knoxville, Tenn.

[21] Appl. No.: **410,581**

[22] Filed: **Mar. 30, 1995**

Related U.S. Application Data

[63] Continuation of Ser. No. 4,828, Jan. 15, 1993.

[51] **Int. Cl.**[6] **A61K 31/20**

[52] **U.S. Cl.** **514/547**; 554/224

[58] **Field of Search** 514/547; 554/224

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,302,447	11/1981	Horrobin	424/145
4,526,902	7/1985	Rubin	514/560
4,528,197	7/1985	Blackburn	514/552
4,607,052	8/1986	Mendy et al.	514/547
4,701,469	10/1987	Mendy et al.	514/547
4,752,618	6/1988	Mascioli et al.	514/549
4,753,963	6/1988	Jandacek et al.	514/552
4,758,592	7/1988	Horrobin	514/549
4,843,095	6/1989	Rubin	514/558
4,871,768	10/1989	Bistrian et al.	514/547
4,888,326	12/1989	Horrobin	514/27
4,898,885	2/1990	Horrobin	514/560
4,906,664	3/1990	Bristrian et al.	514/552
4,931,468	6/1990	Horrobin	514/560
4,965,075	10/1990	Horrobin et al.	424/638
4,970,235	11/1990	Traitler et al.	514/558
5,043,328	8/1991	Weithmann	514/78
5,081,105	1/1992	Bistrian	514/2
5,196,198	3/1993	Shaw et al.	442/195.1
5,227,403	7/1993	Seto et al.	514/547

FOREIGN PATENT DOCUMENTS

2000391	10/1988	Canada .	
421867	of 0000	European Pat. Off. .	
871142972	9/1987	European Pat. Off. .	
0300844	6/1988	European Pat. Off.	C07C 69/587
8901364	3/1989	WIPO .	
8900237	10/1989	WIPO .	
8900239	10/1989	WIPO .	
WO90/04012	10/1989	WIPO	C11C 3/08

OTHER PUBLICATIONS

Hirschberg, et al. "The Response to Endotoxin in Guinea Pigs After Intravenous Blackcurrant Seed Oil". Lipids, vol. 25, 491–495, 1990.

Karlstad et al. "Dietary Manipulation of Plasma Fatty Acid Profiles with γ–Linolenic Acid Enriched Parenteral Nutrition in Injured Rats". J. Parenteral Enteral Nutrition, vol. 16., 25S, 1992, No. S1A.

Primary Examiner—Samuel Barts

Attorney, Agent, or Firm—L. R. Drayer; D. O. Nickey; T. D. Brainard

[57] **ABSTRACT**

There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

6 Claims, No Drawings